New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
17:42 EDTCPHD, RHHBYCepheid says Roche patent suit will not have material adverse impact on results
Cepheid (CPHD) management stated that they have not had the opportunity to review the claim made by Roche (RHHBY) regarding a patent suit filed earlier; however management stated that it is their understanding that the patent has expired. Either way, the lawsuit will not have a material adverse impact on the company's results.
News For CPHD;RHHBY From The Last 14 Days
Check below for free stories on CPHD;RHHBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 25, 2014
07:35 EDTRHHBYEMA recommends new indication for RoActemra in severe arthritis
Subscribe for More Information
July 24, 2014
06:13 EDTRHHBYRoche reaffirms outlook for 2014
Subscribe for More Information
06:12 EDTRHHBYRoche reports 1H core EPS CHF 7.57 vs. CHF 7.58 last year
Subscribe for More Information
July 23, 2014
09:08 EDTRHHBYUltragenyx appoints Sunil Agarwal, M.D. as Chief Medical Officer
Subscribe for More Information
July 22, 2014
05:21 EDTRHHBYRoche announces Genentech Avastin granted priority review by FDA
Subscribe for More Information
July 21, 2014
07:11 EDTRHHBYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
06:43 EDTRHHBYGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 20, 2014
15:42 EDTRHHBYRoche not looking for big acquisitions, Reuters says
Subscribe for More Information
July 18, 2014
09:44 EDTCPHDCepheid trades sharply lower after earnings, levels to watch
Subscribe for More Information
09:24 EDTCPHDOn The Fly: Pre-market Movers
Subscribe for More Information
July 17, 2014
17:42 EDTCPHD, RHHBYCepheid says Roche patent suit will not have material adverse impact on results
Subscribe for More Information
17:31 EDTCPHDCepheid sees significant step up in Q4 revenue
17:31 EDTCPHDCepheid sees Q3 non-GAAP EPS (1c)-1c, consensus (8c)
Subscribe for More Information
16:14 EDTCPHDCepheid sees FY14 adjusted EPS 10c-13c, may not compare to consensus (37c)
Subscribe for More Information
16:13 EDTCPHDCepheid reports Q2 EPS (14c), consensus (14c)
Reports Q2 revenue $116.5M, consensus $115.56M.
July 16, 2014
11:23 EDTRHHBYRoche Alzheimer drug shows mixed results in trial, NYT says
Subscribe for More Information
06:26 EDTRHHBYBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
July 15, 2014
05:37 EDTRHHBYGenentech Avastin granted priority review by FDA
Subscribe for More Information
July 14, 2014
11:20 EDTRHHBYExelixis seen as potential target for Roche, TheStreet says
Subscribe for More Information
08:18 EDTCPHDCepheid Q2 results should beat expectations, says Wedbush
Wedbush thinks the high number of Cepheid's Infinity placements in 4Q13 and Q1 could boost the company's Q2 results. The firm keeps a $58 price target and Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use